

Entrepreneurs: What NOT To Do in Trademarks, Patents, And Trade Secrets!

SPEAKERS



DAVID POWSNER

MODERATOR

dpowsner@DavisMalm.com









NVogler@mofo.com peter.fasse@fr.com todd.gerety@gesmer.com



TODD GERETY



Nathan Vogler, Of Counsel



Nvogler@mofo.com +1 (617) 648-4746

Nathan Vogler is an of counsel in the firm's Patent Group. Nathan's practice concentrates on domestic and international patent prosecution, IP due diligence, IP counseling, IP portfolio management, and IP litigation support including patent infringement and validity determinations.

Nathan has handled matters in all stages of patent prosecution, including new application drafting, office action responses, patent appeals, and continuation and divisional filings. He has drafted and prosecuted patents in various technology areas, including medical devices, polymer chemistry, composite materials, industrial processing, nanotechnology, catalysts, batteries, magnets, consumer electronics, and software. In addition, Nathan has experience handling reexaminations, reissue applications, and supplemental examinations before the United States Patent and Trademark Office.

Nathan received his J.D. with high honors from The George Washington University Law School, where he was elected to the Order of the Coif and was a member of the George Washington Law Review. He received his B.S. in chemical engineering, with a minor in chemistry, summa cum laude from Purdue University. He is admitted to practice in Virginia and is registered to practice before the USPTO.

www.mofo.com/people/nathan-vogler



Peter Fasse

Principal | **Boston, MA** | <u>Online Biography</u> 617-521-7802 fasse@fr.com

J.D., George Washington University Law School

B.S., Massachusetts Institute of Technology; Bioelectrical Engineering and Life Sciences

- Prosecutes patents and counsels clients regarding wide-ranging technologies, with an emphasis on biotechnology, healthcare, medical devices, and other biological and medical fields, as well as various green technologies.
- Helps clients from startups to multinationals develop competitive worldwide patent strategies and establish solid and defensible patent portfolios. He performs competitive patent analyses, identifies third-party patent risks, and provides patentability and freedom to operate opinions.
- Has experience in opposing and defending patents before the European Patent Office and in U.S. litigation and post-grant proceedings.
- Especially broad technical knowledge and experience makes him a go-to lawyer for medical therapeutics and diagnostics devices, and imaging, microfluidic systems, liquid biopsy, cell culturing and bioprocessing, molecular biology, complex biomedical systems, optics, machine tools, lasers, and more.
- Recognized among the "The World's Leading Patent Practitioners" by IAM Patent 1000 (2018 2022).



Fish & Richardson Overview

Established in 1878, Fish has represented many of history's leading innovators, a trend that started early in our history with representing Alexander Graham Bell and the Wright Brothers.

#1 US Firm for IP Litigation

From 2017 to 2022, Fish handled more patent matters in **U.S.** District Courts than any other national firm.

During the same period, Fish was Lead Counsel in 1 of every 6 newly filed ITC Section 337 investigation.

#1 US Firm for Post-Grant Proceedings

Fish was the #1 law firm at the PTAB in 2022

Fish represented petitioners and patent owners in 134 proceedings handling 21 more PTAB cases overall than its closest competitor.

Global Patent Prosecution Firm

Fish filed 17.800+ U.S. and foreign patent applications in 2022.

Fish obtained more U.S. utility patents in 2022 than any other firm, securing 5,244 patents nearly 600 more than its nearest competitor.

Fish is a potent force in litigation, a leader in post-grant proceedings and a global prosecution powerhouse.

The firm doesn't just have handfuls of people dotted around the country, but teams stacked with accomplished trial lawyers and high-level strategists in innovation hubs from coast to coast.

-IAM Patent 1000, 2021

